These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

656 related articles for article (PubMed ID: 22939034)

  • 21. Safety and Tolerability of Linagliptin in Patients With Type 2 Diabetes: A Comprehensive Pooled Analysis of 22 Placebo-controlled Studies.
    Lehrke M; Marx N; Patel S; Seck T; Crowe S; Cheng K; von Eynatten M; Johansen OE
    Clin Ther; 2014 Aug; 36(8):1130-46. PubMed ID: 25015594
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Linagliptin improved glycaemic control without weight gain or hypoglycaemia in patients with type 2 diabetes inadequately controlled by a combination of metformin and pioglitazone: a 24-week randomized, double-blind study.
    Bajaj M; Gilman R; Patel S; Kempthorne-Rawson J; Lewis-D'Agostino D; Woerle HJ
    Diabet Med; 2014 Dec; 31(12):1505-14. PubMed ID: 24824197
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study of the efficacy and tolerability of combination therapy with rosiglitazone and sulfonylurea in African American and Hispanic American patients with type 2 diabetes inadequately controlled with sulfonylurea monotherapy.
    Davidson JA; McMorn SO; Waterhouse BR; Cobitz AR
    Clin Ther; 2007 Sep; 29(9):1900-14. PubMed ID: 18035190
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety and efficacy of the dipeptidyl peptidase-4 inhibitor linagliptin in elderly patients with type 2 diabetes: a comprehensive analysis of data from 1331 individuals aged ≥ 65 years.
    Schernthaner G; Barnett AH; Patel S; Hehnke U; von Eynatten M; Woerle HJ
    Diabetes Obes Metab; 2014 Nov; 16(11):1078-86. PubMed ID: 24865132
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study.
    Moretto TJ; Milton DR; Ridge TD; Macconell LA; Okerson T; Wolka AM; Brodows RG
    Clin Ther; 2008 Aug; 30(8):1448-60. PubMed ID: 18803987
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Canagliflozin in Conjunction With Sulfonylurea Maintains Glycemic Control and Weight Loss Over 52 Weeks: A Randomized, Controlled Trial in Patients With Type 2 Diabetes Mellitus.
    Yale JF; Xie J; Sherman SE; Garceau C
    Clin Ther; 2017 Nov; 39(11):2230-2242.e2. PubMed ID: 29103664
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and safety of initial combination therapy with linagliptin and pioglitazone in patients with inadequately controlled type 2 diabetes: a randomized, double-blind, placebo-controlled study.
    Gomis R; Espadero RM; Jones R; Woerle HJ; Dugi KA
    Diabetes Obes Metab; 2011 Jul; 13(7):653-61. PubMed ID: 21410628
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Triple therapy with glimepiride in patients with type 2 diabetes mellitus inadequately controlled by metformin and a thiazolidinedione: results of a 30-week, randomized, double-blind, placebo-controlled, parallel-group study.
    Roberts VL; Stewart J; Issa M; Lake B; Melis R
    Clin Ther; 2005 Oct; 27(10):1535-47. PubMed ID: 16330290
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Combination of empagliflozin and linagliptin as second-line therapy in subjects with type 2 diabetes inadequately controlled on metformin.
    DeFronzo RA; Lewin A; Patel S; Liu D; Kaste R; Woerle HJ; Broedl UC
    Diabetes Care; 2015 Mar; 38(3):384-93. PubMed ID: 25583754
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and safety of linagliptin in Asian patients with type 2 diabetes mellitus inadequately controlled by metformin: A multinational 24-week, randomized clinical trial.
    Wang W; Yang J; Yang G; Gong Y; Patel S; Zhang C; Izumoto T; Ning G
    J Diabetes; 2016 Mar; 8(2):229-37. PubMed ID: 25753488
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects.
    Sarashina A; Sesoko S; Nakashima M; Hayashi N; Taniguchi A; Horie Y; Graefe-Mody EU; Woerle HJ; Dugi KA
    Clin Ther; 2010 Jun; 32(6):1188-204. PubMed ID: 20637971
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Linagliptin: a review of its use in the management of type 2 diabetes mellitus.
    Deeks ED
    Drugs; 2012 Sep; 72(13):1793-824. PubMed ID: 22913735
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor linagliptin in black/African American patients with type 2 diabetes: Pooled analysis from eight Phase III trials.
    Thrasher J; Kountz DS; Crowe S; Woerle HJ; von Eynatten M
    Postgrad Med; 2015 Jun; 127(5):419-28. PubMed ID: 25840727
    [TBL] [Abstract][Full Text] [Related]  

  • 34. DPP-4 inhibitors in the management of type 2 diabetes: a critical review of head-to-head trials.
    Scheen AJ
    Diabetes Metab; 2012 Apr; 38(2):89-101. PubMed ID: 22197148
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and safety profile of glimepiride in Mexican American Patients with type 2 diabetes mellitus: a randomized, placebo-controlled study.
    Luis Bautista J; Bugos C; Dirnberger G; Atherton T
    Clin Ther; 2003 Jan; 25(1):194-209. PubMed ID: 12637120
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Vildagliptin added to sulfonylurea improves glycemic control without hypoglycemia and weight gain in Chinese patients with type 2 diabetes mellitus.
    Yang W; Xing X; Lv X; Li Y; Ma J; Yuan G; Sun F; Wang W; Woloschak M; Lukashevich V; Kozlovski P; Kothny W;
    J Diabetes; 2015 Mar; 7(2):174-81. PubMed ID: 24823599
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study.
    Taskinen MR; Rosenstock J; Tamminen I; Kubiak R; Patel S; Dugi KA; Woerle HJ
    Diabetes Obes Metab; 2011 Jan; 13(1):65-74. PubMed ID: 21114605
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and safety of gemigliptin, a dipeptidyl peptidase-4 inhibitor, in patients with type 2 diabetes mellitus inadequately controlled with combination treatment of metformin and sulphonylurea: a 24-week, multicentre, randomized, double-blind, placebo-controlled study (TROICA study).
    Ahn CH; Han KA; Yu JM; Nam JY; Ahn KJ; Oh TK; Lee HW; Lee DH; Kim J; Chung CH; Park TS; Kim BJ; Park SW; Park HK; Lee KJ; Kim SW; Park JH; Ko KP; Kim CH; Lee H; Jang HC; Park KS
    Diabetes Obes Metab; 2017 May; 19(5):635-643. PubMed ID: 28026912
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Initial combination of linagliptin and metformin improves glycaemic control in type 2 diabetes: a randomized, double-blind, placebo-controlled study.
    Haak T; Meinicke T; Jones R; Weber S; von Eynatten M; Woerle HJ
    Diabetes Obes Metab; 2012 Jun; 14(6):565-74. PubMed ID: 22356132
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of adding linagliptin to basal insulin regimen for inadequately controlled type 2 diabetes: a ≥52-week randomized, double-blind study.
    Yki-Järvinen H; Rosenstock J; Durán-Garcia S; Pinnetti S; Bhattacharya S; Thiemann S; Patel S; Woerle HJ
    Diabetes Care; 2013 Dec; 36(12):3875-81. PubMed ID: 24062327
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 33.